NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DC-20-008 from the NIH Guide for Grants and Contracts
Notice NOT-DA-20-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-20-037 from the NIH Guide for Grants and Contracts. Advancing Genomic Medicine Research (Clinical Trial Optional) (R21) This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care, irrespective of participants ancestral origins or sociodemographic status. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting.
Funding Opportunity RFA-HG-20-036 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care, irrespective of participants ancestral origins or sociodemographic status. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting.
Notice NOT-AT-20-014 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-115 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-116 from the NIH Guide for Grants and Contracts
Notice NOT-MH-20-061 from the NIH Guide for Grants and Contracts
Notice NOT-MH-20-059 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-113 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-211 from the NIH Guide for Grants and Contracts. The OppNet Research Career Enhancement Award (K18) program invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathwaysexpertise that is beyond and enhances their current areas of expertise. The program will support research training and career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Eligible candidates are independent investigators at mid-career faculty rank or level.
Funding Opportunity PAR-20-226 from the NIH Guide for Grants and Contracts. The OppNet Research Career Enhancement Award (K18) program invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathwaysexpertise that is beyond and enhances their current areas of expertise. The program will support research training and career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Eligible candidates are independent investigators at mid-career faculty rank or level.
Notice NOT-MD-20-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AA-20-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders.
Funding Opportunity RFA-DK-20-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications for the George M. OBrien Urology Cooperative Research Centers Program (U54). This program will foster multi- and interdisciplinary collaboration between basic, translational, and clinical researchers with diverse expertise to address questions of underlying etiology and biological and clinical features of benign genitourinary conditions within the NIDDKs mission. In addition, the program will serve as a national resource for the larger urologic research community and provide opportunities for educational enrichment and engagement of investigators in pilot projects that target innovative science and researchers new to urology. All efforts will address the overall goal of improving prevention and clinical management of benign genitourinary disorders through research excellence, enhanced sharing of resources and access to core services, and establishment of a robust research community trained to address the Nations biomedical, behavioral, and clinical research needs for benign genitourinary conditions.
Notice NOT-MH-20-048 from the NIH Guide for Grants and Contracts
Notice NOT-MH-20-060 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-21-003 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications are expected to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans. Successful applicants proposing the use of adult stem cells as a clinical intervention will be asked to make available representative samples of the source stem cell and clinical-grade stem cell-derived product for in-depth and independ
Notice NOT-GM-20-028 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-21-013 from the NIH Guide for Grants and Contracts. This funding opportunity announcement invites computational HIV/AIDS research as it relates to NIDAs mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. An R01 research project should build on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD).